Lung-MAP: A beacon of hope for lung cancer patients

The unique public-private partnership that for almost a decade has undergirded the first National Cancer Institute (NCI)-sponsored precision medicine clinical trial in lung cancer can serve as a model for future clinical research that is more rapid, innovative, and inclusive.

Related Keywords

Oregon ,United States ,Charlesd Blanke ,Roys Herbst ,Ellenv Sigal , ,National Clinical Trials Network ,Genentech ,Friends Of Cancer Research ,Bristol Myers Squibb Company ,Astrazeneca ,National Institutes Of Health ,Cancer Research Network ,Amgen ,Science University ,Yale School Of Medicine ,Clinical Cancer Research ,Yale Cancer Center ,Pfizer ,Foundation For The National Institutes Of Health ,Swog Cancer Research Network ,Foundation Medicine ,Oregon Health ,National Cancer Institute ,Lung Cancer Master Protocol ,Clinical Cancer ,Smilow Cancer Hospital ,Ensign Professor ,Yale School ,National Institutes ,Research Network ,Cancer Research ,Clinical Trials Network ,Patients Enrolled ,Lung Cancer Master ,Trial Diversity ,Arc Toward ,Research ,Dancer ,Fell ,Clinical Trial ,Drugs ,Enetic ,Enomic ,Hospital ,Lung Cancer ,Medicine ,Non Small Cell Lung Cancer ,Ncology ,Precision Medicine ,Small Cell Lung Cancer ,Humor ,